To include your compound in the COVID-19 Resource Center, submit it here.

Triplet debuts with $59M, therapies for repeat expansion disorders

Triplet aims to treat repeat expansion disorders by targeting the DNA damage response pathway

When new research emerged last year pegging the DNA damage response pathway as a main driver of repeat expansion disorders, rather than the genetic mutations themselves, Atlas Venture co-founded and seeded Triplet with $10 million to design therapies based on the research. The company debuted Tuesday with a $49 million series A led by MPM Capital and Pfizer Ventures.

Atlas, Invus, Partners Innovation

Read the full 624 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE